Emergent BioSolutions Inc. · NYSE:EBS

Emergent BioSolutions — Q3 2026 Earnings Presentation

35 slides from Emergent BioSolutions's earnings presentation, Nov 2, 2026

  1. Slide 1: 2026 Third Quarter Financial Results

    Slide 1: 2026 Third Quarter Financial Results

    ® 2026 Third Quarter Financial Results Our Mission: Protect and Save Lives November 2, 2026 1

  2. Slide 2: Safe Harbor Statement and Trademarks

    Slide 2: Safe Harbor Statement and Trademarks

    Safe Harbor Statement and Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any

  3. Slide 3: Today's Agenda

    Slide 3: Today's Agenda

    Today’s Agenda Presenter Topic Joe Papa Multi-Year Transformation Plan Update President and CEO Q3 2026 Business Performance & Key Highlights Rich Lindahl Q3 2026 Financial Results & Full-Year Guidance EVP, Chief Financial Officer Joe Papa 2026 Growth Catalysts President and CEO Q&A Session 3

  4. Slide 4: EBS: The Most Diverse Biodefense/MCM and Naloxone Products Globally

    Slide 4: EBS: The Most Diverse Biodefense/MCM and Naloxone Products Globally

    EBS: The Most Diverse Biodefense/MCM and Naloxone Products Globally1 Smallpox • ACAM2000® • TEMBEXA® • 25+ years of experience developing and manufacturing protections • CNJ-016® (VIGIV) Ebola against critical public health threats • Ebanga® • Vast experience working with the U.S. and allied governm

  5. Slide 5: Multi-Year Transformation Plan Update

    Slide 5: Multi-Year Transformation Plan Update

    Multi-Year Transformation Plan Update Joe Papa President and Chief Executive Officer 5

  6. Slide 6: Our Multi-Year Transformation Plan

    Slide 6: Our Multi-Year Transformation Plan

    Our Multi-Year Transformation Plan Turnaround Priorities Transformation Goals • Focus on segment revenue growth and improved operating • Advance strategic transformation for long-term growth and profitability performance • Build synergistic verticals to further leverage EBS infrastructure • Invest i

  7. Slide 7: 2026 Business Performance & Key Highlights

    Slide 7: 2026 Business Performance & Key Highlights

    2026 Business Performance & Key Highlights Joe Papa President and Chief Executive Officer 7 7

  8. Slide 8: Continued Execution on Turnaround Plan

    Slide 8: Continued Execution on Turnaround Plan

    Continued Execution on Turnaround Plan Q3 2026 performance results - consistent with expectations Strong Financial Performance Business Results & Key Initiatives ü FY 2026 Q3 Revenues of $110M - within prior guidance range ü Solid MCM performance driven by accelerated contract awards and product del

  9. Slide 9: AI Revives New Biologic Threat Risks, Demanding Stronger Biosecurity

    Slide 9: AI Revives New Biologic Threat Risks, Demanding Stronger Biosecurity

    AI Revives New Biologic Threat Risks, Demanding Stronger Biosecurity A Call for Partnership Emergent aims to collaborate with AI companies on bioterrorism preparedness Potential Initiatives • AI for health preparedness council: cross-sector partnership involving Emergent, technology companies, feder

  10. Slide 10: Strong Engagement with U.S. and International Governments on Biodefense Preparedness

    Slide 10: Strong Engagement with U.S. and International Governments on Biodefense Preparedness

    Strong Engagement with U.S. and International Governments on Biodefense Preparedness Key Highlights • MCM Q3 2026 revenue of $59M total • Awarded contract modification valued at approximately $24M for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted); delivered product shipments ahead of schedule to

  11. Slide 11: Leading Critical Efforts in the U.S. and Canada to Help Reduce Opioid Overdose Deaths

    Slide 11: Leading Critical Efforts in the U.S. and Canada to Help Reduce Opioid Overdose Deaths

    Leading Critical Efforts in the U.S. and Canada to Help Reduce Opioid Overdose Deaths Landscape Insights Market Leadership in U.S. Public Interest & Canada • U.S. and Canada still experiencing persistent and evolving shifts • OTC NARCAN® Nasal Spray 4 mg continues to be a standard of care; with opio

  12. Slide 12: Q3 2026 Financial Results & Full-Year Guidance

    Slide 12: Q3 2026 Financial Results & Full-Year Guidance

    Q3 2026 Financial Results & Full-Year Guidance Rich Lindahl EVP, Chief Financial Officer 12

  13. Slide 13: Key Financial Performance Metrics Q3 2026 vs. Q3 2025

    Slide 13: Key Financial Performance Metrics Q3 2026 vs. Q3 2025

    Key Financial Performance Metrics Q3 2026 vs. Q3 20251 Total revenues consistent with prior guidance Q3 YoY influenced by timing of MCM deliveries (Q2 2026 vs Q3 2025) Total Revenues Adjusted EBITDA & Adjusted EBITDA Margin 2 $231 40% ($ in millions) ($ in millions) $110 $93 (4)% $(5) Q3 2025 Q3 202

  14. Slide 14: Notable Revenue Elements Q3 2026 vs. Q3 2025

    Slide 14: Notable Revenue Elements Q3 2026 vs. Q3 2025

    Notable Revenue Elements Q3 2026 vs. Q3 20251 ($ in millions) Q3 2025 Q3 2026 $231 $217 $84 $75 $110 $57 $103 $44 $25 $27 $7 $14 $7 $1 Naloxone Anthrax MCM Smallpox MCM Other Total Product Sales, All Other Revenue 3 Total Revenue Products net 2 1. All financial information incorporated within this p

  15. Slide 15: Key Financial Performance Metrics YTD 2026 vs. YTD 2025

    Slide 15: Key Financial Performance Metrics YTD 2026 vs. YTD 2025

    Key Financial Performance Metrics YTD 2026 vs. YTD 20251 Results in-line with expectations and highlight continued cost discipline Total Revenues Adjusted EBITDA & Adjusted EBITDA Margin2 $594 $500 34% ($ in millions) ($ in millions) 25% $205 $128 YTD 2025 YTD 2026 YTD 2025 YTD 2026 Adjusted Gross M

  16. Slide 16: Notable Revenue Elements YTD 2026 vs. YTD 2025

    Slide 16: Notable Revenue Elements YTD 2026 vs. YTD 2025

    Notable Revenue Elements YTD 2026 vs. YTD 20251 ($ in millions) YTD 2025 YTD 2026 $545 $468 $594 $500 $231 $188 $193 $139 $65 $77 $61 $59 $49 $32 Naloxone Anthrax MCM Smallpox MCM Other Total Product Sales, All Other Revenue3 Total Revenue Products net 2 1. All financial information incorporated wit

  17. Slide 17: Disciplined Balance Sheet Management During Turnaround in 2026

    Slide 17: Disciplined Balance Sheet Management During Turnaround in 2026

    Disciplined Balance Sheet Management During Turnaround in 20261 Cash & Liquidity YoY Material Debt Reduction3,4 Gross Debt4 $68M utilized to $693 Net Debt 3,4 $346 ($ in millions) ($ in millions) repurchase Bonds Revolver $514 $100 $448 $226 $339 $75M Unsecured Bond Principal repurchased Revolver $5

  18. Slide 18: Strong Cash Generation Enables Significant Deleveraging

    Slide 18: Strong Cash Generation Enables Significant Deleveraging

    Strong Cash Generation Enables Significant Deleveraging Generated $352M of cumulative operating cash flow through Q3 2026 and reduced net debt 3,4 by $418M vs. YE 2023 1 Gross Debt4 Net Debt3,4 Cumulative Operating Cash Flow $352 $868 $757 $229 $514 $339 Net Leverage 2,3 Q3 2023: 15.9x $59 Q3 2026:

  19. Slide 19: YTD Capital Allocation Update

    Slide 19: YTD Capital Allocation Update

    YTD Capital Allocation Update Prioritized Focus Areas Growth Investments • International MCM growth plan • Internal R&D investments (~$50M investment in Ebanga® milestone) • Business development opportunities Debt Refinancing & Reduction • Completed April 2026 term loan refinancing Debt Management •

  20. Slide 20: FY 2026 Revenue & Profitability Guidance

    Slide 20: FY 2026 Revenue & Profitability Guidance

    FY 2026 Revenue & Profitability Guidance FY 2026 as of FY 2026 as of FY 2026 as of FY 2026 as of METRIC ($ in millions) Action November 2, 2026 August 5, 2026 April 30, 2026 February 26, 2026 Total revenues $600 - $645 REVISED1 $645 - $675 $720 - $760 $720 - $760 MCM revenues: Impacted by expected t

  21. Slide 21: 2026 Business Outlook & Catalysts to Enable Growth

    Slide 21: 2026 Business Outlook & Catalysts to Enable Growth

    2026 Business Outlook & Catalysts to Enable Growth Joe Papa President and Chief Executive Officer 21

  22. Slide 22: Key Growth Catalysts

    Slide 22: Key Growth Catalysts

    Key Growth Catalysts We plan to invest in growth opportunities that enable sustainable and long-term growth. Exploring potential for government-funded R&D programs. Selectively evaluating strategically suitable external programs. Emergent is exploring investment opportunities to support AI companies

  23. Slide 23: Near-Term Focus Maximizes Value of Current Assets and Pipeline/R&D Opportunities

    Slide 23: Near-Term Focus Maximizes Value of Current Assets and Pipeline/R&D Opportunities

    Near-Term Focus Maximizes Value of Current Assets and Pipeline/R&D Opportunities Stage of Development Product/Candidate Disease Area Partner(s) Discovery Preclinical Phase 1 Phase 2 Phase 3 Submission Approved Ebanga®* Zaire ebolavirus BARDA ü Smallpox BARDA ü TEMBEXA® Mpox PANTHER, Africa CDC-led *

  24. Slide 24: Closing Remarks

    Slide 24: Closing Remarks

    Closing Remarks • Continued to deliver on multi-year transformation plan; prioritizing key turnaround actions and achieving financial targets to drive our business forward • EBS believes it can play an important role in partnering with AI leaders against potential bad actors / biological threats, in

  25. Slide 25: Q&A Session

    Slide 25: Q&A Session

    Q&A Session Questions? Answers. 25

  26. Slide 26: End Notes: Non-GAAP Financial Measures

    Slide 26: End Notes: Non-GAAP Financial Measures

    End Notes: Non-GAAP Financial Measures In this presentation, we sometimes use information derived from consolidated and segment financial information that may not be presented in our financial statements or prepared in accordance with generally accepted accounting principles in the United States (“G

  27. Slide 27: End Notes: Non-GAAP Financial Measures (Continued)

    Slide 27: End Notes: Non-GAAP Financial Measures (Continued)

    End Notes: Non-GAAP Financial Measures (Continued) We define Adjusted Gross Margin, which is a non-GAAP financial measure, as Gross Margin, excluding the impact of intangible asset amortization, stock-based compensation expense, severance and restructuring costs (benefits) and inventory step-up prov

  28. Slide 28: Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)

    Slide 28: Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)

    Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) – Q3 2026 vs. Q3 2025(1) Three Months Ended Nine Months Ended September 30, September 30, (unaudited, $ in millions) 2026 2025 2026 2025 Source Net income (loss) $ (32.7) $ 51.2 $ (206.1) $ 107.2 Adjustments: Inventory step-up provisi

  29. Slide 29: Reconciliation of Net Income (Loss) to Adjusted EBITDA

    Slide 29: Reconciliation of Net Income (Loss) to Adjusted EBITDA

    Reconciliation of Net Income (Loss) to Adjusted EBITDA and Net Income (Loss) Margin to Adjusted EBITDA Margin – Q3 2026 vs. Q3 2025(1) Three Months Ended September 30, Nine Months Ended September 30, (unaudited, $ in millions) 2026 2025 2026 2025 Net income (loss) $ (32.7) $ 51.2 $ (206.1) $ 107.2 A

  30. Slide 30: Reconciliations of Total Revenues to Product and Services Sales and Gross Margin

    Slide 30: Reconciliations of Total Revenues to Product and Services Sales and Gross Margin

    APPENDIX Reconciliations of Total Revenues to Product and Services Sales, Net and of Gross Margin and Gross Margin % to Adjusted Gross Margin and Adjusted Gross Margin % – Q3 2026 vs. Q3 2025(1) & YTD 2026 vs. YTD 2025(1) Three Months Ended September 30, Nine Months Ended September 30, ($ in million

  31. Slide 31: Reconciliations of Total Debt to Net Debt and Net Leverage Ratio

    Slide 31: Reconciliations of Total Debt to Net Debt and Net Leverage Ratio

    Reconciliations of Total Debt to Net Debt (1) and Net Leverage Ratio (2) As of As of As of As of (unaudited, $ in millions) September 30, 2026 September 30, 2025 December 31, 2023 September 30, 2023 Total debt $ 514.3 $ 693.1 $ 868.4 $ 866.3 Less: Cash and cash equivalents 175.7 245.5 111.7 87.8 Net

  32. Slide 32: Reconciliation of Net Loss to Adjusted Net Income (Loss) – FY 2026 Forecast

    Slide 32: Reconciliation of Net Loss to Adjusted Net Income (Loss) – FY 2026 Forecast

    Reconciliation of Net Loss to Adjusted Net Income (Loss) – Full Year 2026 Forecast ($ in millions) 2026 Full Year Forecast Source Net loss $(255) - $(225) Adjustments: Inventory step-up provision $5 Cost of products and services, net Severance and restructuring costs 11 Cost of products and services

  33. Slide 33: Reconciliation of Net Loss to Adjusted EBITDA – FY 2026 Forecast

    Slide 33: Reconciliation of Net Loss to Adjusted EBITDA – FY 2026 Forecast

    Reconciliation of Net Loss to Adjusted EBITDA – Full Year 2026 Forecast ($ in millions) 2026 Full Year Forecast Net loss $(255) - $(225) Adjustments: Depreciation & amortization $81 Income taxes 13 Total interest expense, net 38 Inventory step-up provision 5 Severance and restructuring costs 11 Stoc

  34. Slide 34: Reconciliations of Forecasted Revenues and Gross Margin – FY 2026 Forecast

    Slide 34: Reconciliations of Forecasted Revenues and Gross Margin – FY 2026 Forecast

    Reconciliations of Forecasted Total Revenues to Forecasted Product and Services Sales, Net and of Forecasted Gross Margin and Gross Margin % to Forecasted Adjusted Gross Margin and Adjusted Gross Margin % - Full Year 2026 Forecast ($ in millions) 2026 Full Year Forecast Total revenues $600 - $645 Co

  35. Slide 35

    Slide 35

Source: 6ix earnings call

More decks from Emergent BioSolutions Inc.

All 46 Emergent BioSolutions decks